A Trial for the Safety and Effectiveness of a Novel Antimicrobial-Coated Foley Catheter for Reduction of CAUTI.

Urinary Tract Infection Clinical Trial

Official title:

A Randomized Trial for the Safety and Effectiveness of a Novel Antimicrobial-Coated Foley Catheter Attached to an Antimicrobial Anti-Reflux Device for Reduction of Catheter-Associated Urinary Tract Infection

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01681511
• Other study ID #: ICET-001
• Secondary ID: R44DK055891-06
• Status: Terminated
• Phase: N/A
• First received: July 29, 2012
• Last updated: April 9, 2014
• Start date: May 2012
• Est. completion date: January 2013

Study information

• Verified date: April 2014
• Source: Innovative Chemical and Environmental Technologies, Inc
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective of this pilot study is to demonstrate the feasibility of recruiting eligible patients for the purposes of assessing the temporal aspects and rates of Catheter Associated Urinary Tract Infection (CAUTI), based on the agreed-upon case definition so that the numbers needed for a pivotal study can be better estimated.

Description:

This pilot study will be a prospective, single site, randomized clinical investigation comparing the safety and effectiveness of the ICET TIC antimicrobial Foley catheter, against the infection control standard-of-care, the BARD ® LUBRI-SIL® I.C. Foley catheter.

Approximately 160 patients will be screened. The study has been designed to enroll approximately 120 eligible subjects to obtain about 60 evaluable subjects (30 in each arm). Subjects who meet the eligibility criteria will be enrolled into the study and randomly assigned to the experimental or standard-of-care group in a 1:1 ratio.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 100
• Est. completion date: January 2013
• Est. primary completion date: January 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject is at least 18 years of age

2. Subject is expected to be catheterized with 14 or 16 French Foley catheters for at least 72 hours.

3. Subject (or a legally authorized representative) has provided written informed consent for study participation and procedures to be performed.

4. Life expectancy at least 3 months or more in the judgment of the investigator

Exclusion Criteria:

1. Subjects who present with previously known, symptomatic UTI

2. Subjects with a positive urine dipstick at the time of enrollment

3. Subjects who are on systemic antibiotics within 48 hours prior to enrollment

4. Subjects with a known of suspected allergy to silicone, silver or silver compounds causing delayed hypersensitivity reactions or contact dermatitis.

5. Subjects who have had an indwelling catheter removed less than 48 hours before study enrollment.

6. Current genitourinary tract surgery or known infection

7. Subject requires use of a non-study urinary catheter

8. Subjects known to be pregnant or breast feeding at the time of enrollment

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Infection
• Urinary Tract Infection
• Urinary Tract Infections

Intervention

Device:
• ICET™ TIC Foley Catheter
The device to be evaluated in this investigation is a silver-based antimicrobial coated Foley catheter connected to an antimicrobial anti-reflux accessory (ICET Inc, Norwood, MA). The closed system is referred to as the TIC system and is designed with the objective of reducing the incidence of CAUTI. The accessory is non-tissue contacting.
• BARD® LUBRI-SIL® IC Foley Catheter
The LUBRI-SIL® I.C. antimicrobial 100% silicone Foley catheter incorporates a formulation consisting of BACTI-GUARD®* silver alloy coating and BARD® hydrogel.

Locations

Country	Name	City	State
United States	University of Minnesota Fairview medical center	Minneapolis,	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Innovative Chemical and Environmental Technologies, Inc	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Organism Relation to CAUTI and TIC	Organisms found in relation to CAUTI events in TIC versus control.	up to 30th day from the time of catheterization	No
Primary	Number of Subjects Affected, During Treatment and Follow-up Time Periods, by a Catheter Associated Urinary Tract Infection (CAUTI) Event After First CAUTI Event.	All randomized subjects will be followed until (1) up to 30th day from the time of catheterization or (2) the subject withdraws or is discharged from the hospital, whichever comes first and (3) 48 hours after the catheter is removed.; Evaluable population (EP) refers to all randomized subjects successfully CZD & stayed on the CZD for = 48 ± 24 hours or more without any systemic (postoperative) antibiotic for CZD/non-CZD related reasons. Subjects receiving an intercurrent course of systemic antibiotics lasting >24 hours other than surgical prophylaxis were considered non-evaluable in all analyses of effectiveness endpoints using the EP.	up to 30th day from the time of catheterization	No
Primary	The Proportion of Subjects With at Least One CAUTI	CAUTI is as determined by blinded investigator assessment per protocol definition.; DAYS TO CAUTI = (DATE OF EVENT - DATE OF CZD INSERTION) + 1. Date of event for subjects who had CAUTI is the date of urine sample collection where the CAUTI criteria are met.; Date of event for subjects who did not have CAUTI is the last available urine culture collection date from samples collected during & post CZD.; p-values of time of CAUTI were obtained from log-rank test. p-values of Incidence of CAUTI were obtained from the Logistic Regression Model.; Evaluable population (EP) refers to all randomized subjects successfully CZD & stayed on the CZD for = 48 ± 24 hours or more without any systemic (postoperative) antibiotic for CZD/non-CZD related reasons. Subjects receiving an intercurrent course of systemic antibiotics lasting >24 hours other than surgical prophylaxis were considered non-evaluable in all analyses of effectiveness endpoints using the EP.; CZD = Catheterized or catheter	48 ± 24 hours or more	No
Secondary	The Proportion of Subjects With Symptomatic Urinary Tract Infection (SUTI)	Patients with catheter related SUTI are those having an indwelling urinary catheter in place at the time of specimen collection, or had an indwelling catheter within the previous 48 hours, and at least 1 of the following signs or symptoms with no other recognized cause: fever (>38°C), suprapubic tenderness, or costovertebral angle pain or tenderness and a positive urinalysis demonstrated by at least one of the following findings: a. positive dipstick for leukocyte esterase and/or nitrite, b. pyuria (urine specimen collected from the catheter with =10 white blood cells [WBC]/mm3 or =3 WBC/high power field of unspun urine), c. microorganisms seen on Gram stain of unspun urine and a positive urine	up to 30th day from the time of catheterization	No
Secondary	The Proportion of Subjects With Asymptomatic Bacteremic Urinary Tract Infection (ABUTI)	Patients having an indwelling urinary catheter who have no signs or symptoms (i.e., no fever (>38°C), no urgency, frequency, dysuria, suprapubic tenderness, or costovertebral angle pain or tenderness), and a positive urine culture from urine collected from the catheter sampling port (or a midstream voided clean catch urine in subjects being followed for 48 hours post catheter removal) of >105 CFU/ml with no more than 2 species of uropathogen microorganisms and a positive blood culture with at least 1 matching uropathogen microorganism to the urine culture.	up to 30th day from the time of catheterization	No